Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) rose by more than 50% though that wasn’t the same thing for Mylan N.V. (NASDAQ:MYL) .That was on Thursday after FDA reportedly approved the provider’s Epinephrine injection, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (PFS) which as a matter of fact happens to be the generic version of Mylan N.V.’s MYL EpiPen which is the best-selling though has its downside of being a high-cost treatment for life-threatening allergies. While the shares of Adamis were hitting headlines for remarkable performance, those of Mylan went down by about 2.38%.
According to Yahoo.com, the approval body approved the trade name Symjepi for the pre filled syringe which will indeed turn out to be interesting news to all those persons that have been struggling with allergic reactions. Symjepi, which will be providing two single dose syringes, will most probably be hitting markets in the second half of 2017.
Going by the company’s insiders, Symjepi will be sold at a lower cost and will also be distributed in a wide range of sizes in order to fit to the budget of the different users. In Aug 2016, Mylan came under the spotlight for price increase of EpiPen since its acquisition of the drug in 2007 and that sparked a number of top lawyers and consumers to raise concerns. The pressure on the top drug maker to do something about its pricing has been immense with a lot of people anticipating the company’s next move.
In December, Mylan unveiled its first authorized generic for EpiPen Auto-Injector to be sold out at $300 per epinephrine injection USP two-pack, which will be the wholesale acquisition cost (WAC).This is more than 50% lower than the WAC of EpiPen 2-Pak Auto-Injectors and deal that should excite any buyer.
It seems like the company heard the cry of patients and also listened to the lawmakers. Top drug manufacturing companies now more than ever are directing more efforts into coming up with new solutions to help the ailing patients globally. The wild competition between them means well for the various patients.
